Modality
Small Molecule
MOA
SGLT2i
Target
CD38
Pathway
Ferroptosis
WilmsLN
Development Pipeline
Preclinical
Apr 2017
→ Aug 2027
PreclinicalCurrent
NCT03201210
1,524 pts·LN
2023-05→2025-04·Active
NCT05543927
1,969 pts·LN
2017-04→2027-08·Not yet recruiting
3,493 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2611mo agoInterim· LN
2027-08-081.4y awayInterim· LN
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2025-04-26 · 11mo ago
LN
Interim
2027-08-08 · 1.4y away
LN
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03201210 | Preclinical | LN | Active | 1524 | EFS |
| NCT05543927 | Preclinical | LN | Not yet recr... | 1969 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 |